Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Idexx (IDXX) Down 5% Since Last Earnings Report: Can It Rebound?

In This Article:

It has been about a month since the last earnings report for Idexx Laboratories (IDXX). Shares have lost about 5% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Idexx due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.

IDEXX Q4 Earnings and Revenues Top Estimates

IDEXX Laboratories posted fourth-quarter 2024 earnings per share (EPS) of $2.62, up 12.9% year over year. The figure surpassed the Zacks Consensus Estimate by 9.1%.

Comparable constant-currency EPS of $2.53 improved 10% year over year.

Full-year 2024 earnings of $10.67 rose 6.1% from the 2023 level. The figure exceeded the Zacks Consensus Estimate by 2.1%.

IDEXX’s Revenues in Detail

Quarterly revenues increased 5.8% year over year (up 6% organically) to $954.3 million. The reported figure topped the Zacks Consensus Estimate by 1.9%.

The year-over-year upside was primarily driven by Companion Animal Group ("CAG") growth of 6% as reported and organically.

Veterinary software, services and diagnostic imaging systems’ revenues increased 13% on a reported basis and 7% organically.

Full-year total revenues of $3.90 billion improved 6% on a reported basis as well as organically from the 2023 level, driven by 10% reported and 10.5% organic growth in CAG Diagnostics recurring revenues. The figure beat the Zacks Consensus Estimate by a close margin of 0.5%.

IDEXX’s Segmental Analysis

IDEXX derives revenues from four operating segments — CAG, Water, Livestock, Poultry and Dairy (“LPD”), and Other.

CAG revenues rose 6% year over year on a reported basis and on an organic basis to $870.5 million.

CAG Diagnostics’ recurring revenues also increased 6% on a reported basis and 7% organically, reflecting double-digit IDEXX VetLab consumable gains, and solid reference laboratory and consulting services growth.

The Water segment’s revenues increased 8% year over year on a reported and 9% on an organic basis to $45.2 million.

For the fourth quarter, LPD revenues increased 5% reportedly and 7% on an organic basis to $34.6 million.         

Revenues from the Other segment decreased 28.6% on a reported basis to $4.1 million.

IDEXX’s Margin Performance

The gross profit rose 8.5% to $570.7 million. The gross margin expanded 144 basis points (bps) to 59.8% despite a 2.2% rise in the cost of revenues.